When Phase II or III studies demonstrate sub-optimal outcomes or result in failure, assets can be de-prioritized or abandoned, which impacts patient populations who could greatly benefit from the treatment. IQVIA™ pairs end-to-end clinical development expertise with artificial intelligence / machine learning to drive an innovative analytical approach to identifying predictive sub-groups and biomarkers in clinical and real-world data.
Read our factsheet to learn how to:
Increase the probability of rescuing a failing asset
Redesign trial or enable an add-on study
Improve design of next phase trials
Adapt regulatory strategy for a completed study
Manage your asset pipeline for predictable return on investment
Please complete the following form to download the factsheet
